| |
 |
9.3.2008 - Reata to Present at Thomas Weisel Partners Healthcare Conference |
| |
Reata Pharmaceuticals, Inc. announces that its Vice President of Finance, Jason Wilson, will be presenting a company overview on Wednesday, September 3, 2008 at the Thomas Weisel Partners Healthcare Conference at 9:45 a.m., Eastern Time. The event is being held at the Four Seasons Hotel in Boston, MA.
|
|
7.28.2008 - Reata to Present at BMO Capital Markets Healthcare Conference |
| |
Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Wednesday, August 6, 2008 at the BMO Capital Markets "Focus on Healthcare Conference" at 9:00 a.m., Eastern Time. The event is being held at the Milennium Broadway Hotel in New York, New York.
|
|
6.18.2008 - Reata Expands Executive Team to Support Advancing Clinical Programs |
| |
Reata Pharmaceuticals, Inc. announced a substantial expansion of its executive team to take advantage of opportunities from its advancing clinical and preclinical pipelines. Seasoned executives have been added to the team in the areas of clinical development, regulatory affairs, and business development.
|
|
6.1.2008 - ASCO: First-In-Man Study of RTA 402 Yields Promising Results in Patients with Advanced Cancers |
| |
Reata Pharmaceuticals, Inc. announced results from a first-in-man study of RTA 402 in patients with advanced cancers, presented in an oral session at the annual meeting of the American Society for Clinical Oncology. RTA 402 is the clinical lead from Reata's Antioxidant Inflammation Modulators (AIMs), a new and highly promising category of drugs for the treatment of cancer and inflammation. One of the study's Principal Investigators, Dr. David Hong from the University of Texas M. D. Anderson Cancer Center, presented data showing that RTA 402 had an excellent safety profile and provided a clinical benefit in a significant percentage of patients. Investigators also confirmed that the drug was active against its biological targets, NF-kappa B and STAT3. These pro-inflammatory transcription factors promote tumor growth, angiogenesis, invasion, metastasis, and resistance to therapy. Overall, RTA 402 showed a profile of disease control and tumor reduction comparable or superior to any recently approved targeted therapy in a Phase I patient population and a markedly superior side effect profile.
|
|
5.27.2008 - Reata to Present at FBR Capital Markets Investor Conference in NYC on May 29 |
| |
Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Thursday, May 29, 2008 at the FBR Capital Markets 12th Annual Spring Investor Conference. This event is being held at the Grand Hyatt hotel in New York, New York. Mr. Huff's presentation is scheduled for 2:00 pm Eastern Time. The presentation will focus on Reata's two franchise technologies: its AIM platform of novel, broad-spectrum anti-inflammatory agents and its protein folding discovery platform. It will also highlight a number of upcoming Phase 2 data events with Reata's two lead compounds.
|
|
5.22.2008 - 10 New Papers Published on Anti-Cancer Effects of Reata AIMs |
| |
Reata Pharmaceuticals, Inc. announced the publication of 10 separate peer-reviewed papers supporting the use of its Antioxidant Inflammation Modulators (AIMs) in cancer patients. These papers reflect work conducted at leading academic institutions including Dartmouth Medical School, The Burnham Institute, and the Dana-Farber Cancer Institute. Collectively, they further elucidate the novel mechanism of action of the AIMs in cancer, demonstrate effects in a broad array of tumor types, and show consistent activity across multiple structural analogs.
|
|
5.21.2008 - Phase 1 Cancer Results with RTA 402 Scheduled for Oral Presentation at 2008 ASCO |
| |
Results of a Phase 1 clinical trial of RTA 402 in patients with advanced cancers was selected for an oral presentation at the 2008 annual meeting of the American Society of Clinical Oncologists.
|
|
4.11.2008 - Updated Data on Reata's Two Clinical Candidates Presented at
2008 Annual Meeting of the American Association of Cancer Research |
| |
Reata Pharmaceuticals, Inc. announced today the presentation of significant new preclinical data on its two clinical-stage compounds, berubicin hydrochloride (an anthracycline derivative formerly known as RTA 744) and RTA 402 (the lead agent in Reata’s portfolio of Antioxidant Inflammation Modulators, or AIMs, also known as CDDO-Me).
|
|
2.8.2008 - Reata to Present at 2008 BIO CEO and Investor Conference on 2/11 at 2:00 pm |
| |
IRVING, TX - February 8, 2008 - Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Monday, February 11, 2008 at the Biotechnology Industry Organization's CEO and Investor Conference at 2:00 p.m., Eastern Time. The presentation will include an update on the company's portfolio of clinical development programs as well as its best-in-class protein folding discovery platform.
|
|
